{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T03:36:02Z","timestamp":1785036962447,"version":"3.55.0"},"reference-count":25,"publisher":"The Journal of Rheumatology","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2013,11]]},"abstract":"Objective.<\/jats:title>Patients with systemic lupus erythematosus (SLE) are at increased risk of herpes zoster (HZ). Although a vaccine for HZ has been approved by the US Food and Drug Administration, its use in immunocompromised individuals remains controversial because it is a live-attenuated virus vaccine. We performed a pilot study of the immunogenicity of the HZ vaccine (Zostavax) in patients with SLE.<\/jats:p><\/jats:sec>Methods.<\/jats:title>Ten patients with SLE and 10 control subjects \u2265 age 50 years participated in this open-label vaccination study. All were seropositive for varicella zoster virus (VZV). Patients with SLE were excluded for SLE Disease Activity Index (SLEDAI) > 4, or use of mycophenolate mofetil, cyclophosphamide, biologics, or > 10 mg prednisone daily. Followup visits occurred at 2, 6, and 12 weeks. Clinical outcomes included the development of adverse events, particularly HZ or vesicular lesions, and SLE flare. Immunogenicity was assessed with VZV-specific interferon-\u03b3-producing enzyme-linked immunospot (ELISPOT) assays and with antibody concentrations.<\/jats:p><\/jats:sec>Results.<\/jats:title>All subjects were women. Patients with SLE were slightly older than controls (60.5 vs 55.3 yrs, p < 0.05). Median baseline SLEDAI was 0 (range 0\u20132) for patients with SLE. No episodes of HZ, vesicular rash, serious adverse events, or SLE flares occurred. Three injection site reactions occurred in each group: mild erythema or tenderness. The proportion of subjects with a > 50% increase in ELISPOT results following vaccination was comparable between both groups, although absolute SLE responses were lower than controls. Antibody titers increased only among controls following vaccination (p < 0.05).<\/jats:p><\/jats:sec>Conclusion.<\/jats:title>The HZ vaccination yielded a measurable immune response in this cohort of patients with mild SLE taking mild-moderate immunosuppressive medications. No herpetiform lesions or SLE flares were seen in this small cohort of patients.ClinicalTrials.gov<\/jats:ext-link>ID:NCT01474720<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.130170","type":"journal-article","created":{"date-parts":[[2013,9,16]],"date-time":"2013-09-16T00:14:23Z","timestamp":1379290463000},"page":"1875-1880","source":"Crossref","is-referenced-by-count":58,"title":["Herpes Zoster Vaccination in SLE: A Pilot Study of Immunogenicity"],"prefix":"10.3899","volume":"40","author":[{"given":"Joel M.","family":"Guthridge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Cogman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan T.","family":"Merrill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Macwana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista M.","family":"Bean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiny","family":"Powe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza F.","family":"Chakravarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2013,9,15]]},"reference":[{"key":"2018112909320812000_40.11.1875.1","doi-asserted-by":"publisher","DOI":"10.1086\/528696"},{"key":"2018112909320812000_40.11.1875.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23883"},{"key":"2018112909320812000_40.11.1875.3","first-page":"2151","article-title":"Association of reduced CD4 T cell responses specific to varicella zoster virus with high incidence of herpes zoster in patients with systemic lupus erythematosus","volume":"31","author":"Park","year":"2004","journal-title":"J Rheumatol"},{"key":"2018112909320812000_40.11.1875.4","first-page":"274","article-title":"Close association of herpes zoster reactivation and systemic lupus erythematosus (SLE) diagnosis: case-control study of patients with SLE or noninflammatory musculoskeletal disorders","volume":"31","author":"Pope","year":"2004","journal-title":"J Rheumatol"},{"key":"2018112909320812000_40.11.1875.5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel328"},{"key":"2018112909320812000_40.11.1875.6","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.1999.00490.x"},{"key":"2018112909320812000_40.11.1875.7","first-page":"1254","article-title":"Herpes zoster in systemic lupus erythematosus","volume":"22","author":"Manzi","year":"1995","journal-title":"J Rheumatol"},{"key":"2018112909320812000_40.11.1875.8","first-page":"84","article-title":"Herpes zoster infections in systemic lupus erythematosus: risk factors and outcome","volume":"21","author":"Kahl","year":"1994","journal-title":"J Rheumatol"},{"key":"2018112909320812000_40.11.1875.9","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/art.1780210710","article-title":"Herpes zoster in patients with systemic lupus erythematosus","volume":"21","author":"Moutsopoulos","year":"1978","journal-title":"Arthritis Rheum"},{"key":"2018112909320812000_40.11.1875.10","doi-asserted-by":"publisher","DOI":"10.1177\/0961203312470186"},{"key":"2018112909320812000_40.11.1875.11","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1590\/S1807-59322011000700009","article-title":"Risk of herpes zoster in patients with systemic lupus erythematosus: a three-year follow-up study using a nationwide population-based cohort","volume":"66","author":"Chen","year":"2011","journal-title":"Clinics (Sao Paulo)"},{"key":"2018112909320812000_40.11.1875.12","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-011-0162-0"},{"key":"2018112909320812000_40.11.1875.13","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3181d52ed7"},{"key":"2018112909320812000_40.11.1875.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051016"},{"key":"2018112909320812000_40.11.1875.15","unstructured":"US Food Drug Administration . Approval letter \u2013 Zostavax. [Internet. Accessed August 16, 2013.] Available from: http:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm248608.htm"},{"key":"2018112909320812000_40.11.1875.16","doi-asserted-by":"publisher","DOI":"10.1086\/605611"},{"key":"2018112909320812000_40.11.1875.17","first-page":"RR\u20135","article-title":"Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2018112909320812000_40.11.1875.18","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.137216"},{"key":"2018112909320812000_40.11.1875.19","unstructured":"Curtis JR Saag KG Winthrop K . Update on herpes zoster (shingles) vaccine for autoimmune disease patients. [Internet. Accessed August 16, 2013.] American College of Rheumatology Hotline, September 21, 2012. Available from http:\/\/www.rheumatology.org\/Publications\/Hotline\/Update_on_Herpes_Zoster_(Shingles)_Vaccine_for_Autoimmune_Disease_Patients\/"},{"key":"2018112909320812000_40.11.1875.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780251101"},{"key":"2018112909320812000_40.11.1875.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350606"},{"issue":"Suppl 10","key":"2018112909320812000_40.11.1875.22","first-page":"902","article-title":"Revision of the SELENA flare index [abstract]","volume":"60","author":"Petri","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2018112909320812000_40.11.1875.23","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000226841.03751.1f"},{"key":"2018112909320812000_40.11.1875.24","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/AJP.0b013e3181eef686","article-title":"A prospective study of the herpes zoster severity of illness","volume":"26","author":"Drolet","year":"2010","journal-title":"Clin J Pain"},{"key":"2018112909320812000_40.11.1875.25","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2011.357"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.130170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,6]],"date-time":"2022-03-06T06:33:33Z","timestamp":1646548413000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.130170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,15]]},"references-count":25,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2013,11,1]]},"published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.3899\/jrheum.130170"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.130170","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,15]]}}}